Skip to content

Autoimmunity in Patients With GAD-Ab and Their Relatives

Autoimmunity Family Background in Neurological Syndromes With Antibodies Against Glutamic-acid Decarboxylase

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04104620
Acronym
FamilyGAD
Enrollment
100
Registered
2019-09-26
Start date
2019-09-30
Completion date
2020-09-30
Last updated
2019-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurological Syndromes With GAD-Ab, Organ-specific Autoimmune Diseases

Brief summary

A group of poorly studied immune-mediated neurological syndromes are associated with antibodies against glutamic-acid decarboxylase (GAD-Ab). GAD is the rate-limiting enzyme for the synthesis of gamma aminobutyric acid (GABA) from glutamate and is expressed by inhibitory neurons of the central nervous system. Neurological syndromes with anti-GAD antibodies (GAD-Ab) are often non-paraneoplastic. They mainly include limbic encephalitis (LE), cerebellar ataxia (CA) and stiff-person syndrome (SPS). Although the pathogenic role of GAD-Ab is controversial, most patients have high serum levels and GAD-Ab are also detected in the cerebrospinal fluid (CSF) along with other inflammatory abnormalities such as oligoclonal bands. GAD-Ab may also be present in the serum of T1DM patients, as pancreatic beta cells also express GAD, but usually at much lower titers than those of neurological patients. Organ-specific autoimmune diseases, such as T1DM and autoimmune thyroid disease, are common among patients with GAD-Ab and neurological syndromes and in their relatives, suggesting a shared genetic predisposition to autoimmune disorders. This is also supported by family reports of neurological syndromes with GAD-Ab and some HLA associations described in SPS. The aim of this study is to describe the different autoimmune organ-specific diseases present in patients with GAD-Ab and their relatives, along with to identify families with higher aggregation of autoimmune diseases and establish potential ways of inheritability.

Detailed description

A group of poorly studied immune-mediated neurological syndromes are associated with antibodies against glutamic-acid decarboxylase (GAD-Ab). GAD is the rate-limiting enzyme for the synthesis of gamma aminobutyric acid (GABA) from glutamate and is expressed by inhibitory neurons of the central nervous system. Neurological syndromes with anti-GAD antibodies (GAD-Ab) are often non-paraneoplastic. They mainly include limbic encephalitis (LE), cerebellar ataxia (CA) and stiff-person syndrome (SPS). Although the pathogenic role of GAD-Ab is controversial, most patients have high serum levels and GAD-Ab are also detected in the cerebrospinal fluid (CSF) along with other inflammatory abnormalities such as oligoclonal bands. GAD-Ab may also be present in the serum of T1DM patients, as pancreatic beta cells also express GAD, but usually at much lower titers than those of neurological patients. Organ-specific autoimmune diseases, such as T1DM and autoimmune thyroid disease, are common among patients with GAD-Ab and neurological syndromes and in their relatives, suggesting a shared genetic predisposition to autoimmune disorders. This is also supported by family reports of neurological syndromes with GAD-Ab and some HLA associations described in SPS. The aim of this study is to describe the different autoimmune organ-specific diseases present in patients with GAD-Ab and their relatives, along with to identify families with higher aggregation of autoimmune diseases and establish potential ways of inheritability.

Interventions

None listed

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient with a well-known neurological syndrome associated with Gad-Ab (LE, CA, SPS) * Patient with an CSF positive for GAD-Ab; * Patient witn an Age \> 18 years old.

Exclusion criteria

* Patient with absence of complete clinical data. * Patient with CSF not tested or negative for GAD-Ab

Design outcomes

Primary

MeasureTime frameDescription
Autoimmune organ-specific diseases in patients with GAD-Ab and their relatives12 MonthsTo collect the different autoimmune organ-specific diseases present in patients with GAD-Ab and their relatives

Secondary

MeasureTime frameDescription
Inheritability in neurological syndromes with GAD-Ab12 MonthsTo establish potential common ways of inheritability in neurological syndromes with GAD-Ab and organ-specific autoimmune diseases

Contacts

Primary ContactJerome HONNORAT, phd
jerome.honnorat@chu-lyon.fr4 72 35 78 08
Backup ContactGéraldine PICARD
geraldine.picard@chu-lyon.fr4 72 35 58 42

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026